STEMCELL Technologies Acquires Cellular Highways

Bio-Techne Acquires Namocell

June 22, 2022

Medical Devices

Bio-Techne Corporation has agreed to acquire Namocell, Inc., a Mountain View–based provider of single-cell sorting and dispensing platforms, with the deal expected to close in Bio-Techne's fiscal 2023 Q1. Namocell's Pala and Hana systems (installed base approaching 200 placements, ~60 sold in 2021) will complement Bio-Techne's Cell and Gene Therapy franchise and create commercial synergies across its analytical instruments sales force.

QHP Capital Acquires Applied StemCell

October 9, 2023

Biotechnology

QHP Capital has acquired Applied StemCell, a Milpitas, California–based cell and gene therapy CRO/CDMO that provides iPSC and TARGATT gene‑editing platforms for biopharma and research clients. QHP said the acquisition will provide strategic capital and operating support to accelerate ASC's commercial expansion and scale its manufacturing and service capabilities for the cell and gene therapy market.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

BioIVT Acquires BeCytes Biotechnologies

November 4, 2025

Biotechnology

BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.

Tempus Acquires Highline Sciences

February 8, 2022

Healthcare Services

Tempus, the Chicago-based AI-driven precision medicine company, has acquired Highline Sciences, a San Francisco-based full-service clinical CRO focused on oncology. The acquisition will allow Tempus to vertically integrate additional clinical trial services and expand its capabilities to support and grow clinical research offerings for oncology therapeutics.

Celly H2 Acquires Chemtec New Energies from Chemtec Energy Services

July 30, 2024

Renewable Energy

Celly H2 LLC has acquired Chemtec New Energies (CNE), a renewable-energy focused division of Chemtec Energy Services LLC, to expand its hydrogen fueling and storage infrastructure capabilities. The deal brings CNE's modular refueling and storage expertise into Celly's portfolio to accelerate deployment of modular advanced hydrogen refueling stations (MAHRS) for municipalities, transit authorities, fleets, industrial users and ports.